Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-14T23:46:33.740Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug attitude inventory is relevant to LAI treatment persistence in schizophrenia: Preliminary results

Published online by Cambridge University Press:  13 August 2021

G. D’Anna ,
L. Tatini ,
F. Pietrini ,
A. Ballerini  and
V. Ricca
G. D’Anna*
Affiliation:
Department Of Health Sciences, University of Florence, Florence, Italy
L. Tatini
Affiliation:
Department Of Health Sciences, University of Florence, Florence, Italy
F. Pietrini
Affiliation:
Department Of Mental Health And Addictions, Central Tuscany NHS Trust, Florence, Italy
A. Ballerini
Affiliation:
Department Of Health Sciences, University of Florence, Florence, Italy
V. Ricca
Affiliation:
Department Of Health Sciences, University of Florence, Florence, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Patients’ attitudes and subjective experience are crucial in the management of severe mental illness, but their practical value is overlooked.

Objectives

To identify predictors of future adherence to LAI antipsychotic maintenance treatment of schizophrenia among socio-demographic, clinical, and psychometric characteristics – including Drug Attitude Inventory-10 (DAI-10) and Subjective Well-being under Neuroleptics short form (SWN-K) scores.

Methods

Retrospective baseline data from 53 clinically stable outpatients with schizophrenia switched from oral to LAI therapy were collected. Patients continuing treatment at the time of analysis (n=29) were compared to those who had discontinued it (n=24). Selected variables were further evaluated in survival analyses.

Results

Between-group differences are presented in Table 1 (**: p<0.01; *: p<0.05).

Continued treatmentDiscontinued treatmentχ2 or t
Treatment persistence (months)63.79±21.0123.88±25.806.21**
Age (years)39.17±10.1135.58±13.391.11
Male15 (51.7%)13 (54.1%)0.03
Single20 (69.0%)15 (62.5%)0.25
Instruction (years)13.28±3.3111.83±3.561.53
Employed20 (69.0%)7 (29.2%)8.32**
Illness duration (years)17.69±10.5313.42±11.361.42
Previous hospitalisations2.10±1.322.67±1.86-1.29
MADRS13.59±9.0614.67±8.99-0.43
YMRS5.52±5.576.00±9.94-0.22
p-PANSS12.17±5.2014.38±6.13-1.41
n-PANSS10.90±5.3915.63±7.93-2.48*
g-PANSS29.38±10.3333.63±10.26-1.49
PANSS52.66±17.5763.96±20.61-2.15*
DAI-103.86±4.96-1.13±5.803.38**
SWN-K74.93±23.0781.00±15.60-1.09

Cox regression analysis included instruction, employment, hospitalisations, PANSS subscales and DAI-10 scores: a protective role against treatment discontinuation was outlined only for employment (HR 0.16; 95%CI 0.05-0.50) and higher DAI-10 scores (HR 0.85; 95%CI 0.78-0.94). DAI-10 scores delineated distinct adherence trajectories (Figure 1).

Conclusions

Baseline DAI-10 scores may identify patients at risk of dropout after switching to LAI.

Disclosure

No significant relationships.

Keywords

Drug Attitude InventoryadherenceschizophréniaLAI
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S156
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.